Breast cancer vaccine may reduce risk of death

	Tweet

A small trial of an experimental vaccine designed to trigger the immune system to fight breast cancer suggests that it may reduce the risk of death for most patients, U.S. military researchers said on Sunday.

The vaccine, designed to treat women with tumors that generate a protein called HER-2, has been licensed to Scottsdale, Arizona-based Apthera Inc under the brand name NeuVax.

If results from this 163-patient study are validated in a larger trial, the vaccine may offer a new therapy for the largest subset of breast cancer patients, said Linda Benavides, a resident in general surgery at Brooke Army Medical Center in San Antonio, Texas, and the study’s lead researcher.

About 25 percent to 30 percent of women with breast cancer have tumors that express high levels of HER-2. Their tumors tend to grow faster and are more likely to recur than tumors that do not carry the protein.

Most of these women are currently treated with Herceptin, also known as trastuzumab, an expensive antibody-based drug made by Genentech Inc.

Researchers at Brooke Army Medical Center in San Antonio, Texas tested NeuVax in women whose tumors generated low levels of HER-2 as well as women with high levels of the protein.

At 30 months follow-up, the injected vaccine was shown to cut the risk of death for all patients by half, and in the group of patients with low-expressing HER-2 tumors, no deaths were reported. Due to the small size of the study, the survival results were not statistically significant.

The study, presented here at a meeting of the American Association for Cancer Research (AACR), also showed that cancer recurred in 10.7 percent of vaccinated low-expressors, compared with 18.2 percent of the control group.

Benavides said that a planned Phase III trial of NeuVax in more than 700 patients will test the vaccine solely in women with tumors that generate low levels of HER-2—a group for which immune-targeting therapy is currently unavailable.

But these breast cancer patients already have a better prognosis than women with high levels of the protein, leading to questions about whether the results can be duplicated in a larger trial.

“The surprising result is that it was the low-expressing patients who had the better outcomes ... that makes it difficult to interpret the data,” said Dr. William Hait, AACR president and head of oncology research at Johnson & Johnson’s Ortho Biotech unit.

Benavides said the experimental vaccine offers a “very simplistic approach,” toward targeting HER-2, adding that it would be “very cheap to mass produce.”

The wholesale price for Herceptin, which had U.S. sales of $1.3 billion last year, is around $40,000 a year.

By Deena Beasley
SAN DIEGO (Reuters)

RELATED STORIES:
New breast cancer test under study   Breast cancer risk gene discovery fast tracked by new technology   Racial Disparities Exist in Radiation Therapy Rates For Early Stage Breast Cancer   Papillary lesions of the breast should be surgically excised to avoid missing a cancer   New way to predict cancer returning?   One-in-five women would consider breast removal   Eisai says drug active in advanced breast cancer   Breast cancer kills more black women   UCSF team discovers new way to predict breast cancer survival and enhance effectiveness of treatment   Mom should not hide her cancer from the kids   Metabolic Factors May Play a Role in Risk for Breast Cancer   Ovarian cysts linked to lower breast cancer risk   Male breast cancer worse for blacks than whites   Exercise Improves Quality of Life for People with Breast Cancer   Breast cancer treatments impact work status   Improving understanding of cell behaviour in breast cancer   Intake of Vitamin D, Calcium Associated With Lower Risk of Breast Cancer Before Menopause   Breast cancer may not change lifespan for older women   No cancer risk seen with breast implants   Early detection and improved treatment have contributed almost equally to the substantial decrease i   Targeting MMPs to halt advanced metastatic breast cancer   Most women don’t regret preventive mastectomy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]